Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AB.PA
- Price
- 1.44
- Stock movement down
- -0.00 (-0.30%)
- Company name
- AB Science S.A
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 87.76M
- Ent value
- 131.27M
- Price/Sales
- 41.61
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -22.94%
- 1 year return (CAGR)
- -7.53%
- 3 year return (CAGR)
- -40.02%
- 5 year return (CAGR)
- -38.81%
- 10 year return (CAGR)
- -19.07%
Last updated: 2026-02-13
DIVIDENDS
AB.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 41.61 |
| Price to Book | - |
| EV to Sales | 62.24 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 66.18M |
| EPS (TTM) | -0.25 |
| FCF per share (TTM) | -0.20 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.11M |
| Gross profit (TTM) | 1.76M |
| Operating income (TTM) | -14.40M |
| Net income (TTM) | -14.58M |
| EPS (TTM) | -0.25 |
| EPS (1y forward) | -0.13 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 83.31% |
| Operating margin (TTM) | -682.74% |
| Profit margin (TTM) | -691.42% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 5.03M |
| Net receivables | 196.00K |
| Total current assets | 12.32M |
| Goodwill | 0.00 |
| Intangible assets | 1.11M |
| Property, plant and equipment | 0.00 |
| Total assets | 21.22M |
| Accounts payable | 9.56M |
| Short/Current long term debt | 19.08M |
| Total current liabilities | 18.39M |
| Total liabilities | 48.54M |
| Shareholder's equity | -27.32M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -11.12M |
| Capital expenditures (TTM) | 454.00K |
| Free cash flow (TTM) | -11.79M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -68.73% |
| Return on Invested Capital | 59.71% |
| Cash Return on Invested Capital | 48.28% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.34 |
| Daily high | 1.34 |
| Daily low | 1.32 |
| Daily Volume | 55K |
| All-time high | 21.95 |
| 1y analyst estimate | 5.08 |
| Beta | 1.38 |
| EPS (TTM) | -0.25 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 11 May 2026 |
Downside potential
Loading...
Downside potential data
| AB.PA | S&P500 | |
| Current price drop from All-time high | -93.46% | -0.89% |
| Highest price drop | -96.48% | -56.47% |
| Date of highest drop | 11 Dec 2024 | 9 Mar 2009 |
| Avg drop from high | -53.48% | -10.86% |
| Avg time to new high | 289 days | 12 days |
| Max time to new high | 3345 days | 1805 days |
COMPANY DETAILS
Marketcap
87.76M
Marketcap category
Small-cap
Description
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer's disease, and indolent systemic mastocytosis, as well as in Phase 2 trial for mast cell activation syndrome and sickle cell disease. It also develops AB8939, a microtubule destabilizer in Phase 1 trial for the treatment of acute myeloid leukemia; and AB12319 in preclinical trial to treat sarcoma and solid tumors. In addition, the company markets its masitinib under the Masivet brand for the treatment of mast cell tumors in dogs in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
Employees
36
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotech ad...
February 10, 2026
PRESS RELEASE AB SCIENCE ANNOUNCES THAT THE FDA HAS GRANTED THE STATUS OF MINOR USE IN MAJOR SPECIES DESIGNATION FOR MASIVET IN THE TREATMENT OF CANINE MAST CELL TUMORS AB SCIENCE PRESENTS PERSPECTIVE...
February 9, 2026
PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA ...
January 29, 2026
PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT MASI...
January 21, 2026
PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...
January 7, 2026
PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECT...
December 22, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010...
December 18, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES AND CHARACTERIZES A NOVEL SMALL SYNTHETIC MOLECULE, AB8939, AS A PROMISING DRUG CANDIDATE FOR TREATING REFRACTORY ACUTE ...
December 15, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES NEW PUBLICATION ON MEDRXIV HIGHLIGHTING CLINICAL BENEFIT WITH MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS PATIENTS PRIOR ANY COMPLETE LOSS OF FUNCTION Significant imp...
December 11, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.8 MILLION PRIVATE PLACEMENT AB SCIENCE IS FULLY FINANCED TO FINISH PHASE 1 OF AB8939 IN AML AND TO EXECUTE AN EXPANSION PHASE TO...
October 17, 2025
Next page